Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05346809 · ClinicalTrials.gov registry record · Phase 2
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
A Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Divaya Bhutani.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT05346809: Recruiting Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Divaya Bhutani.
NCT05346809 is a Phase 2 study of Multiple Myeloma and Lymphoma that is actively recruiting participants, run by Divaya Bhutani. The registered enrollment target is 39 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05346809, a Phase 2 study of Multiple Myeloma and Lymphoma, is actively recruiting participants, sponsored by Divaya Bhutani.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
Primary Outcome
Change in total lymphocyte count measured from blood sample
Conditions Studied
Interventions
- DRUG Isatuximab
- OTHER Standard Procedures
Study Locations (2)
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT05346809 shows while recruiting
NCT05346809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Isatuximab is the first listed.
NCT05346809 reports a single indexed study location in Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05346809 about?
NCT05346809 is a clinical study titled "Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma". The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transpla...
What is the current status of trial NCT05346809?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2023-03-31. Estimated completion is 2026-09.
What conditions does trial NCT05346809 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult.
What interventions are being tested in trial NCT05346809?
The interventions under investigation include: Isatuximab (DRUG), Standard Procedures (OTHER).
Who is sponsoring clinical trial NCT05346809?
This trial is sponsored by Divaya Bhutani, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05346809 being conducted?
This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05346809's enrollment target sits among peer trials
39 305th of 438 higher than 131 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI